Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

  • This share is currently suspended. It was suspended at a price of 6.75
  • There is currently no data for DCTA

Covid-19 Update

23 Mar 2020 07:00

RNS Number : 1214H
Directa Plus PLC
23 March 2020
 

23 March 2020

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Directa Plus plc

("Directa Plus", "the Group" or the "Company")

 

COVID-19 Update

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, notes the announcement by the Italian Government to close down all productive activity that is not "strictly necessary, crucial, indispensable, to guarantee us essential goods and services." Directa Plus is classified as a chemical company in Italy and as such is exempt from any restrictions and will continue to operate its core business.

 

The Company continues to actively support the Italian authorities, at both local and national level, in their struggle to combat the Covid-19 emergency by making available its technologies. Directa Plus's graphene is non-toxic and its bacteriostatic properties could be used in the production of medical devices such as masks, gloves and gowns to ensure better prevention properties for the spread of the virus.

 

Commenting, Giulio Cesareo, CEO and Founder, said, "Medical equipment enhanced by graphene could mean a safer working environment for the health workers and all citizens. In the health industry graphene is well known for antibacterial and filtering properties and we will continue to develop protective devices using our non-toxic G+ graphene to benefit our fellow citizens during this emergency."

 

This announcement has been approved by Giulio Cesareo, Chief Executive, on behalf of the Company.

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Marco Ferrari, CFO

 

 

 

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

+44 20 7894 7000

Rick Thompson, Philip Davies, Will Goode (Corporate Finance)

 

Caspar Shand Kydd (Sales)

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Mark Taylor, Lauren Kettle

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUUAARROUOUUR
Date   Source Headline
28th May 20267:00 amRNSCancellation - Directa Plus plc
27th Apr 20266:00 pmRNSDirecta Plus
27th Apr 20263:21 pmRNSAppointment of Administrators
14th Apr 20267:00 amRNSUpdate on Funding
13th Apr 20267:43 amRNSUpdate on Further Funding
13th Apr 20267:42 amRNSSuspension - Directa Plus PLC
30th Mar 20267:00 amRNSUpdate on Funding
20th Mar 20267:00 amRNSAIM Rule 17 and Schedule 2(g) update
27th Feb 20267:00 amRNSUpdate on Funding and Board change
7th Jan 20267:00 amRNSFull year trading and operational update
15th Dec 20253:26 pmRNSGrant of 2025 LTIP Awards
24th Sep 20257:00 amRNSHalf Year Report
17th Sep 20257:00 amRNSNotice of interim results presentations
4th Aug 202511:26 amRNSPDMR Dealing
4th Aug 20257:00 amRNSHalf Year Trading Update and Notice of Results
30th Jun 20255:03 pmRNSResult of AGM
19th Jun 20257:00 amRNSDirector/PDMR Shareholding
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
16th Jun 20253:27 pmRNSDirector/PDMR Shareholding
16th Jun 202511:34 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSNotice of Investor Presentation
6th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20257:00 amRNSFinal Results
28th May 20257:00 amRNSNotice of Results
14th Apr 20257:00 amRNSContract Win
7th Apr 20257:00 amRNSTrading and Operational Update & Notice of Results
10th Feb 20257:00 amRNSSetcar secures a new contract win and a renewal
19th Nov 20247:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20247:00 amRNSHalf-year Report
13th Sep 20247:00 amRNSNotice of Results
26th Jul 20244:33 pmRNSResult of General Meeting
4th Jul 20242:24 pmRNSNotification of major holdings
2nd Jul 20244:23 pmRNSNotification of major holdings
1st Jul 20243:16 pmRNSNotification of major holdings
28th Jun 20243:09 pmRNSDirectors’ Participation in Fundraising
28th Jun 20242:57 pmRNSHolding(s) in Company
28th Jun 202412:09 pmRNSPosting of Annual Report & Accounts
27th Jun 20243:50 pmRNSResult of AGM & GM
26th Jun 20247:00 amRNSFinal Results
24th Jun 20247:00 amRNSUpdate on Voting & Action to be Taken
12th Jun 20241:06 pmRNSPosting of Circular and Notice of General Meeting
11th Jun 202410:40 amRNSResult of Placing and Subscription
11th Jun 20247:00 amRNSProposed equity raise
3rd Jun 20247:00 amRNSNotice of AGM
29th May 20247:00 amRNSGipave selected for Rome 2025 Jubilee project
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.